BiotechTube

Interferon γ-1b + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Friedreich's Ataxia

Conditions

Friedreich's Ataxia

Trial Timeline

Jun 1, 2015 → Nov 1, 2016

NCT ID
NCT02415127

About Interferon γ-1b + Placebo

Interferon γ-1b + Placebo is a phase 3 stage product being developed by Amgen for Friedreich's Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT02415127. Target conditions include Friedreich's Ataxia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02415127Phase 3Completed

Competing Products

11 competing products in Friedreich's Ataxia

See all competitors
ProductCompanyStageHype Score
Interferon γ-1bAmgenPhase 3
76
interferon γ-1bAmgenPhase 3
76
varenicline + placeboPfizerPhase 2/3
64
Lu AA24493 + PlaceboLundbeckPhase 2
49
OmeveloxoloneBiogenPre-clinical
20
Placebo + EPI-743 400 mg + EPI-743 200 mgPTC TherapeuticsPhase 2
49
SGT-212Solid BiosciencesPhase 1
25
idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69
Idebenone + Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69
IdebenoneSanthera PharmaceuticalsPhase 3
69
Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84